Lumos Pharma Inc (LUMO) USD0.01
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
- Add to watchlist
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
Business summary
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
Contact details
Important dates
General stock information
- Short code:
- LUMO
- ISIN:
- US55028X1090
- Market cap:
- $19.34 million
- Shares in issue:
- 8.12 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.